396 related articles for article (PubMed ID: 21420951)
1. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
[TBL] [Abstract][Full Text] [Related]
2. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
3. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
5. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
Shim KS; Ma CJ; Kim DS; Ma JY
J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
[TBL] [Abstract][Full Text] [Related]
6. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone.
Ghayor C; Correro RM; Lange K; Karfeld-Sulzer LS; Grätz KW; Weber FE
J Biol Chem; 2011 Jul; 286(27):24458-66. PubMed ID: 21613210
[TBL] [Abstract][Full Text] [Related]
8. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells.
Ko SY
Arch Oral Biol; 2012 Dec; 57(12):1623-32. PubMed ID: 22795564
[TBL] [Abstract][Full Text] [Related]
9. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
[TBL] [Abstract][Full Text] [Related]
10. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss.
Guan H; Zhao L; Cao H; Chen A; Xiao J
FASEB J; 2015 Mar; 29(3):1092-101. PubMed ID: 25466887
[TBL] [Abstract][Full Text] [Related]
11. Low-magnitude high-frequency vibration inhibits RANKL-induced osteoclast differentiation of RAW264.7 cells.
Wu SH; Zhong ZM; Chen JT
Int J Med Sci; 2012; 9(9):801-7. PubMed ID: 23136544
[TBL] [Abstract][Full Text] [Related]
12. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
[TBL] [Abstract][Full Text] [Related]
13. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
14. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Rahman MM; Bhattacharya A; Fernandes G
J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
[TBL] [Abstract][Full Text] [Related]
15. Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation.
Rodrigues WF; Madeira MF; da Silva TA; Clemente-Napimoga JT; Miguel CB; Dias-da-Silva VJ; Barbosa-Neto O; Lopes AH; Napimoga MH
Br J Pharmacol; 2012 Apr; 165(7):2140-51. PubMed ID: 21950592
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of mechanical strain on osteoclastogenesis and osteoclast-related gene expression in RAW264.7 cells.
Xu XY; Guo C; Yan YX; Guo Y; Li RX; Song M; Zhang XZ
Mol Med Rep; 2012 Aug; 6(2):409-15. PubMed ID: 22580758
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells.
Nagasawa T; Arai M; Togari A
Arch Oral Biol; 2011 Sep; 56(9):924-31. PubMed ID: 21377143
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis.
Zhao D; Shi Z; Warriner AH; Qiao P; Hong H; Wang Y; Feng X
PLoS One; 2014; 9(7):e102706. PubMed ID: 25032991
[TBL] [Abstract][Full Text] [Related]
19. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
[TBL] [Abstract][Full Text] [Related]
20. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
